STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
44
13F, latest reported quarter
What the filings say about MDWD
Insiders, 180 days
+$136.0K net bought
3 buyers · 1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$50.3K
1 notice
MediWound insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, MediWound Ltd. insiders bought a net $136.0K of stock across 8 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.
Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 29, 2026.
No other insider sold within 30 days.
44 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Rubinstein Samuel sold about $6.7K of MDWD on Sep 1, 2026, the largest insider sale at the company on our record; 44 funds added in the latest 13F quarter.
First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 0.4% of the 49,990 shares held after it.
2 other insiders bought within 30 days.
44 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SHAMIR NACHUM bought about $2.4K of MDWD on Jun 3, 2026; 2 other insiders bought within 30 days and 44 funds added in the latest 13F quarter.
First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 10.4% of the 55,815 shares held after it.
2 other insiders bought within 30 days.
44 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SHAMIR NACHUM bought about $81.5K of MDWD on Jun 3, 2026, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 44 funds added in the latest 13F quarter.
First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 8.4% of the 20,476 shares held after it.
2 other insiders bought within 30 days.
44 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Fox David Morton bought about $24.6K of MDWD on Jun 1, 2026, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 44 funds added in the latest 13F quarter.
8 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Nobody has filed for crossing 5%. That is a fact, not missing data.
MDWD planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Shmulik Hess
Filed 2026-08-28
$50.3K
MDWD mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco NASDAQ Future Gen 200 ETF
$63.7K position · as of 2026-05-31
0.3%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND
$121.3K position · as of 2026-05-31
0.0%
Small Cap Index Fund
$78.9K position · as of 2026-06-30
0.0%
Global X Russell 2000 ETF
$69.1K position · as of 2026-07-31
0.0%
VANGUARD RUSSELL 2000 INDEX FUND
$721.4K position · as of 2026-05-31
0.0%
Nuveen Small Cap Blend Index Fund
$152.5K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 2
2 active
3
Phase 3
1 active
1
Not applicable
0 active
What changed recently
Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Plac
2026-10-14 · Completion moved 2027-12-30 → 2028-11-04
Phase 2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $136.0K bought by insiders over 180 days, 44 funds added last quarter, $50.3K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
MDWD ranks highest on insider conviction (83rd percentile) and institutional and government (45th), and lowest on risk and compliance (13th), among Pharma & Biotech peers.
Insider conviction
83
Inputs
Net Form 4 buying (codes P and S), 180d$136K · 77 pct, sector of 428
Insider buyers, 180d3 · 89 pct, sector of 437
Institutional and government
45
Inputs
Funds adding, latest quarter44 · 45 pct, sector of 698
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
13
Inputs
Short interest, % of float+20.8% · 13 pct, sector of 813
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Financial health, Growth, US patents
Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
Financial health needs 1 of 2 inputs, 0 present: no debt line filed
Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MDWD filings, in plain words
Are MediWound insiders buying or selling MDWD?
In the 180 days to 2026-10-27, MediWound insiders were net buyers, a net $136.0K: $142.7K of purchases and $6.7K of sales reported on Form 4, by 3 buyers and 1 seller.
Are there planned insider sales of MDWD?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $50.3K of stock; the latest, by Shmulik Hess, was filed 2026-08-28.
Read the full summary
In the 180 days to 2026-10-27, MediWound insiders were net buyers of MDWD, a net $136.0K across purchases and sales reported on Form 4 by 3 buyers and 1 seller. Purchases outweighed sales more than tenfold by value. 3 insiders reported purchases in that window. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $50.3K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.
